@Article{Pyka2012,
journal="Reumatologia/Rheumatology",
issn="0034-6233",
volume="50",
number="1",
year="2012",
title="The role of anticentromere antibodies in diagnosis of rheumatic and cancer diseases",
abstract="Autoantibodies to centromere proteins (CENPs) were first described in 1980 in limited cutaneous SSc (lcSSc) patients. Since that time a number of CENPs have been identified as autoantibody targets in many rheumatic and cancer diseases (Table I, Fig. 1). The general method for detection of anti-centromere antibodies (ACA) is indirect immunofluorescence using HEp-2 cell slides. Autoantibodies CENP-A, -B, -C are relatively specific biomarkers for lcSSc (CREST syndrome). This review focuses on updating information on CENP antibodies against particular autoantigens and their new clinical associations: anti-CENP-A with early Ssc, anti-CENP-D IgM with SLE + Sjögren syndrome, anti-CENP-H (in SSA/SSB negative patients) and anti-CENP-C with Sjögren syndrome. Anti-CENP-F antibodies have totally different clinical significance and occur mainly in cancer diseases.",
author="Pyka, Joanna
and Horbacz, Iwona
and Biernacka, Elwira
and Ząbek, Jakub",
pages="52--56",
url="https://www.termedia.pl/The-role-of-anticentromere-antibodies-in-diagnosis-of-rheumatic-and-cancer-diseases,18,18301,1,1.html"
}